DIAGNOSTIC REPORT

agilus»
diagnostics
PATIENT NAME HAFIZA BEGUM REF, DOCTOR : DR, RATHINDRA NATH BISWAS
coDE/NAME & ADDRESS IC000111042 ACCESSION NO :0269XD000334 |AGE/SEx :48 Years Female
sURE & CURE DIAGNOSTICS |PATILNT D HAFIM2405750 DRAWN :04/04/2024 12:56:53
ALARING NO, 2440, PANDUA SIATION BAZAR, CLIINT PATIENTID: RECEIVED :04/04/2024 16:15:48
POST OFICE LANE,P,S, PANDUA, REPORTED :04/04/2024 19:48:18
HOOGHLY 712149 ABHA N0
9434562382

|Test Report Status Final Results Biological Reference Interval Units

HAEMATOLOGY - CBC

CBC WAIH LSR (CBC+PS+ESR)\ EDIA WHOLE BLOOD/SMEAR

BLOOD coUNTS,EDTA WHOLE BLOOD
12.3 12.0 - 15.0 g/dL
HEMOGLOBIN (HB)
RED BLOOD CELL (RBC) COUNT 4.46 3.8 - 4.8 mil/uL
12.95 High 4.0- 10.0 thou/uL
WHITE BLOOD CELL (WBC) COUNT
156 150- 410 thou/uL
PLATELET COUNT

RBC AND PLATELET INDICES

37.9 36.0 - 46.0
HEMATOCRIT (PCV) fL
MEAN CORPUSCULAR VOLUME (MCV) 85.0 83.0- 101.0
MEAN CORPUSCULAR HEMOGLOBIN (MCH) 27.5 27.0 - 32.0 pg

MEAN CORPUSCULAR HEMOGLOBIN 32.3 31.5- 34.5 g/dL

cONCENTRATION (MCHC) 11,6 - 14.0 %
RED CELL DISTRIBUTION WIDTH (RDW) 15.7 High
MENTZER INDEX 19.1
12,4 H0gh 6.8- 10.9 fL
MEAN PLATELET VOLUME (MPV)

WBC DIFFERENTIAL COUNT

NEUTROPHILS 66 40-80
%
LYMPHOCYTES 27 20 - 40
5 2- 10 %
MONOCYTES
EOSINOPHILS 2 1-6
BASOPHILS 00 0-1 %

ABSOLUTE NEUTROPHIL COUNT 8.61 High 2.0-7.0 thou/uL

ABSOLUTE LYMPHOCYTE COUNT 3.49 High 1.0 - 3.0 thou/uL
ABSOLUTE MONOCYTE COUNT 0.61 0.2 - 1.0 thou/uL
ABSOLUTE EOSINOPHIL COUNT 0.21 0.02 - 0.50 thou/uL
ABSOLUTE BASOPHIL COUNT 0.04 0.02 - 0.10 thou/uL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) 2.5

Page 1 Of 8

Dr, Kauslk Das

Consutent- Pathologlst cum
Laboratory Hend

Vlew Detalls Vlew Report

PERFORMED AT:
Agilus Dlagnostics Ltd.
Prabhat Sandhys Appt, Gr Floor, Mouza- Marlgala, Ward No 13, Distrlct Hooghly
Dankuni, 712311 PatientTE00000078120
West Bengal, India
Tel 9111591115, Fax : CIN - U74899PB1995PLC045956
DIAGNOSTIC REPORT

agilus>
diagnostics
PATIENT NANE HAFIZA BEGUM REF. DOCTOR: DR, RATHINDRA NATH BISWAS
CODE /NANE & ADDRESS :CO00111042 ACCESSION NO:0269XD000334 AGE/SEX :48 Years Fernale
SURE & CURE DIAGNOSTICS 0PATIENT ID HAFIM2405750 DRAWN 04/04/2024 12:56:53
BEARING NO, 2440, PANDUA STATION BAZAR, cUENT PATIENT ID: RECEIVED 04/04/2024 16:15:48
POST OFFICE LANE,P.S. PANDUA,
ABHA NO REPORTED :04/04/2024 19:48: 18
HOOGHLY 712149
9434562382

Results Biological Reference Interval Units

Test Report Status Final

PERIPHERAL SMEAR EXAM, EDTA WHOLE BLOOD

PREDOMINANTLY NORMOCYTIC NORMOCHROMIC
RBC
NORMAL MORPHOLOGY
WBC
PLATELETS
ADEQUATE

Interprtation(s) increase in MCV and HCT 0S observed leading

BLOOD coUNTS EDTA WHOLE BLOOD-The cel morphology is well preserved for 24hrs. However after 24-48 hrs a progressive incr
accårate differential count and for examination of RBC morp
to a decease in MCHC. A direct smear is recommended for anautomated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)
RRC AND PATE FT INDICES-Mentzer index (MCVRBC) 0s an
from Beta thalassaemia at
suspiclon, Estimatlon of HbA2 remains the gold standard for
(<13) in petients wth microcyticanaemia. This needs to be interpreted in line with clinical correlation and
diagnosng a case off tbeta thalassaemia trait.
WBC DIFERENTIAL COUNT-The ontma! threshold pf 3.3 for NLR showed
a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive
and NLR e
mild disease might become severe. By contrast, when age < 49.5 years old
patients. When age = 49.5 years old and NLR = 3.3, 46,1% COVID-19 patients with
3.3. COVID-19 patents tend to show mild disease.
anc PLR in COVID-19 patients A, -P. Yang, et al. International Immunopharmacology 84 (2020) 106504
(Reference to - The dagnostic and pred1ctive role of NLR, d-NLR and
Ths rato element is a calcuiated paremeter and out of NABL Scope.

Page 2 of 8

Dr. Kauik Das

Consutant - Pathologist cum
Laboratory Head
Vlew Details View Report
PERFORMED AT:
Agitus Diagnostics Ltd.
Prabhat Sandhya Appt, Gr Floor,Mouza- Marlgala, Wad No 13, District Hooghly Patient Ref, No, 775000D0070778120
Dankuni, 712311
West Bengal, India
Tel : 9111591115, Fax: CIN - U74899PB1995PLCO45956
 DIAGNOSTIC REPORT

agilus>»
diagnostics
PATIENT NAME: HAFIZA BEGUM REF, DOCTOR: DR, RATHINDRA NATH BISWAS
CoDE/NAME &ADDRESS :CO00111042 IAGE/SEX 48 Years Female
ACCESSION NO :0269XD000334
SURE & CURE DIAGNOSTICS
BEARINGNO, 2440, PANDUA STATION BAZAR, 0PATIENT ID :HAFIM2405750 DRAWN :04/04/2024 12:56:53
POST OFFCE LANE,P.S. PANDUA, CLIENT PATIENT ID: RECEIVED :04/04/2024 16:15:48
HOOGHLY 712149 ABHANO IREPORTED :04/04/2024 19:48:18
9434562382

Test Report Status Final Results BiologicalReference Interval Units

HAEMATOLOGY
CBC WITH ESR (CBC+PS+ESR) EDTA WHOLE BLOOD/SMEAR
ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA
BLOOD
E.S.R 45 High 0 - 20 mm at 1 hr
METHOD:MODIFIED WESTERGREN

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION:
Erythrocyte sedimentatlon rate (ESR) Is a test that Indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall
(sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that
are present at the top portion of the tube after one hour, Nowadays fully automated instruments are available to mcesure ESR.
ESR IS not diegnostic
inflammatory it isa isnon-specific
condition,CRP superior to test
ESR that may itbeis elevated
because in anumber
more sensitive of different
and reflects a moreconditions. It provides
rapid change. general information about the presence of an
TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,
Estrogen mecication, Aging.
Finding a very accelerated ESR{>100 mnm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,
Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).
in pregnancyBRI in first trimester is D-48 mm/hr(62 if anemic) and in second trimester (0-70 mm fhr(95 if anemic), ESR returns to nomal 4th week post partum.
Decreased in: Potycythermia vera, Sickle cell anemia

LIMITATIONs

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poik1locytosis, (SickleCels,spherocytes),Microcytosis, Low fibrinogen, Very high wec counts, Drugs{Quinine,
salicylates)
REFERENCE :
1. Nathan and Oski's Haematology of Infancy and Childhood,Sth edition 2. Paediatric reference intervals. AAcC Press, 7th edition, Edited by S. Soldin 3. The referen ce for
the adut reference range is "Practical Haematology by Dacie and Lewis,10th edition.

Page 3 Of 8

Dr. Kausik Das

Consultant - Pathologist cum
Laboratory Head

View Details View Report

PERFORMED AT :
Agilus Diagnostics Ltd
Prabhat Sandhya Appt, Gr Floor, Mouza- Marigala, Ward No 13, District Hooghly
Dankuni, 712311 Patient Ref, No 775000002078120
West Bengal, India
Tel: 9111591115, Fax : CIN U74899PB1995PLCO45956
 DIAGNOSTIC REPORT

agilus> dagnostics
PATIENT NAME: HAFIZA BEGUM REF. D0CTOR : DR, RATHINDRA NATH BISWAS
CODE/NAME &ADDRESS :C000111042
ACCESSION NO :0269XD000334 AGE/SEX 48 Years Fernale
SURE & CURE DIAGNOSTICS
0PATIENT ID HAFIM2405750 DRAWN .04/04/2024 12:56:53
BEARING NO, 2440, PANDUA STATION BAZAR,
POST OFFICE LANE,P.S. PANDUA, CUENT PATIENT ID: RECEIVED :04/04/2024 16.15:48
HOOGHLY 712149 |ABHA NO !REPORTED :04/04/2024 19:48:18
9434562382

Test Report Status Final Results Biological Reference Interval Units

BIOCHEMISTRY
VER EUNCTIONLPROFILE, SERUM

BILIRUBIN, TOTAL 0.45 0.3- 1.2 mg/dL

METHOD:JENDRASSIK AND GROFF
BILIRUBIN, DIRECT 0.23 0.00 0.40 mg/dL
BILIRUBIN, INDIRECT 0.22 0.1 - 1.0 mg/dL
TOTAL PROTEIN 7.70 6.4 - 8.3 g/dL
METHOD:BIURET
ALBUMIN 4.4 3.5 -5.2 g/dL
GLOBULIN 3.3 2.3 - 3.5 g/dL
ALBUMIN/GLOBULIN RATIO 1.3 1.0 - 2.1 RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) 28 0.0 - 31.0 U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) 57 High 0,0 - 34.0 U/L
ALKALINE PHOSPHATASE 84 42 - 98 U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) 21 0.0 - 38.0 U/L
METHOD: INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY METHOD
LACTATE DEHYDROGENASE 381 225 - 450 U/L
METHOD: PYRUVATE TO LACTATE

Interpretation(s)
LIVER FUNCTION PROFILE, SERUM
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabollsm. Bilirubin is excreted in bile and urine, and elevated levels may give
yeliow discoloration in jaundice.Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased biirubin excretion (eg,
obstruction and hepatitis), and abnormal bilrubin metabolsm (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated
(indirect) bilirubin in Viral hepatitis, Drug reactions, Alcohollc lver disease Conjugated (direct) billrubin is also elevated more than unconjugated (indirect) bilirubin when
there is some kind of biockage af the bile ducts like in Galstones geting into the bile ducts, tumors &Scaring of the bile ducts. Increased unconjugated (indirect) bilirubin
may be a resut of Hemolytic or pernicious anemia, Transfusion reaction &a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that
attaches sugar molecules to bilirubin,
AST is an enzyme found in varnous parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured
dinically as a marker for liver health, AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemoytic
anemia,pancreatitis,hemochrofmatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood,ALT
is found mainly in the iver, but also in smaller amounts in the kidneys, heart,muscles, and pancreas.It is commonly measured as a part of a diagnastic evaluation of
hepatocellular injury, to deterrn1ne Iver health.AST levels increase during acute hepatitis,sometimes due to a viral infection,ischemia to the liver.chronic
hepatitis, obstruction of bile ducts,cirrhosis.
ALP is a tein found in almost allbody tissues.Tissues with higher amounts of ALP include the liver, bile ducts and bone.Elevated ALP levels are seen in Biliary obstruction,
Osteoblastic bone tumors,osteomalacia, hepattis, Hyperparathyroidism,Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen
in Hypophosphatasia, Malnutrition,Protein defldency, Wllsons disease.
GGT is an enzyme found in cetl membranes of many tissues mainly in the liver,kidney and pancreas.It is also found in other tissues including intestine,spleen, heart, brain
and seminal vesicles.The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity.Serum GGT has been widely used as an
index of liver dysfunction.Elevated serum GGT sctivity can be found in diseases of the lver,llary system and pancreas.Conditions that increase serum GGT are otbstructive
liver disease,high aicohol consumption and use of enzyme-inducing drugs etc.
Total Protein aso known as total protein1, is a biochernical test for measunng the total arnount of proteirn in serum.Protein in the plasma is made up of albumin and

Kauaik bas Page 4 Of 8

Dr. Kausik Das

Consultant - Pathologist cum
Laboratory Head

View Detalls View Report

PERFORMED AT:
Agilus Diagnostics Ltd.
Prabhat i,Sandhya Appt,Gr Floor, Mouza- Marigala, Ward No 13, District Hooghly PatiantRe No, 77500000707810
Dankuni, 712311
West Bengal, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLCO45956
 DIAGNOSTIC REPORT

agilus>> diagnostics

PATIENT NAME: HAFIZA BEGUM REF, D0CTOR:DR, RATHINDRA NATH BISWAS

cODE/NAME & ADDRESS :CO00111042 ACCESSION NO : 0269XD000334 |AGE/SEX :48 Years Female
SURE & CURE DIAGNOSTICS
0PATIENT ID HAFIM2405750 DRAWN :04/04/2024 12:56:53
BEARING NO. 2440, PANDUA STATION BAZAR,
POST OFFICE LANE,P.S, PANDUA, CLIENT PATIENTID: RECEIVED :04/04/2024 16:15:48
HOOGHLY 712149 IABHA NO REPORTED :04/04/2024 19:48:18
9434562382

Test Report Status Einal Results BiologicalReference Interval Units

globulin.Higher-than-normal levels may be due to cinflammation or infection,including HIV and hepatitis Bor C, Multiple myeloma,
disease.Lower-than -nomal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage).Burns,Glomerulonephritis,Liver disease, Malabsorption, Malnutritlon,Nephrotic
syndrome, Protein-losing enteropathy etc.
Albumin is the most abundant protein in human blood plasma.It is produced in the llver.Albumin constitutes about half of the blood serum proteln.Low blood albumin levels
(hypoalbuminemia)can be caused by:Liver disease ike cirrhosls of the liver, nephrotic syndrome,protein-losing enteropathy, Burns,hemodilution,increased vascular
permeability or decreassed lymphatic clearance, malnutrition and wasting etc

Kamaik Bas Page 5 Of 8

Dr. Kausik Das

Consutant - Pathologist cum
Laboratory Head

View Details View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
Prabhat Sandhya Appt, Gr FHoor,Mouza- Marigala, Ward No 13, District Hooghly
Dankuni, 712311 Patient Ref. No, 27500000Z078120
West Bengal, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLCO45956
 DIAGNOSTIC REPORT

agilus>» diagnostics

PATIENT NAME: HAFIZA BEGUM REF. DOCTOR:DR, RA THINDRA NATH BISWAS

cODE/NAME &ADDRESS CO00111042 |ACCESSION NO :0269XD000334 iAGE/SEX 48 Years Female
SURE & CURE DIAGNOSTICS 0PATIENT ID HAFIM2405750 DRAWN :04/04/2024 12:56:53
BEARING NO. 2440, PANDUA STATION BAZAR.
CLIENT PATIENT ID: RECEIVED :04/04/2024 16:15:48
POST OFFICE LANE,P.S. PANDUA,
HOOGHLY 712149 ABHA NO REPORTED :04/04/2024 19:48: 18
9434562382

Test Report Status Final Results Biological Reference Interval Units

BIOCHEMISTRY - LIPID

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL 152 < 200 Desirable mg/dL
200- 239 Borderline High
>/= 240 High
TRIGLYCERIDES 86 < 161 Normal mg/dL
161 - 199 High
200 - 499 Hypertriglyceridemia
> or = 500 Very High
METHOo:ENZYMATIC ASSAY
HDL CHOLESTEROL 52 42.0 - 88.0 mg/dL
LDL CHOLESTEROL, DIRECT 93 <100 Optimal mg/dL
100 - 129
Near or above optimal
130 - 159
Borderline High
160 - 189
High
>/= 190
Very High
METHOD : DIRECT HOMOGENOUS
NON HDL CHOLESTEROL 100 Desirable: Less than 130 mg/dL
Above Desirable: 130 - 159
Borderline High: 160 - 189
High: 190 - 219
Very high: > or = 220
VERY LOWDENSITY LIPOPROTEIN 17.2 < 30 mg/dL
CHOL/HDL RATIO 2.9 Low 3.3 - 4.4 Low Risk
4.5-7.0 Average Risk
7.1 - 11.0 Moderate Risk
> 11.0 High Risk
LDL/HDL RATIO 1.8 0.5-3.0 Desirable/Low Risk
3.1 - 6.0 Borderline/Moderate
Risk
> 6.0 High Risk

Page 6 Of 8

Dr. Kaudk Das

Consutant - Pathologist cum
Laboratory Head

View Details View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
Prabhat Sandhya Appt, Gr Floor, Mouza- Marlgala, Ward No 13, Distrlct Hooghly PatienfRe No. 775000002078i20
Dankuni, 712311
West Bengal, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 DIAGNOSTICREPORT

agilus>» dragnostics

PATIENT NAME: HAFIZA BEGUM REF. D0CTOR : DP, RATHINDRA NATH BrsWAS
cCODE/NAME & ADDRESS :C000111042 ACCESSION NO : 0269XDO00334 AGE/SEX 48 Years Female
sURE & CURE DIAGNOSTICs DRAWN 04/04/2024 12:56:53
BEARING NO. 2440, PANDUA STATION BAZAR, PATIENT ID HAFIM2405750
POST OFICE LANE,P.S. PANDUA, CUENT PATIENT ID: RECEIVED 04/04/2024 16:15:48
HOOGHLY 712149 ABHA NO REPORTED :04/04/2024 19:48:18
9434562382

Test Report Status Einal Results Biological Reference Interval Units

CHOLESTEROL, TOTAL

339

271.2

Dordertinetigh
203.4

128 152
135.6

desirable
67.8

30-DEC-2023 14:24 04-APR 2024 19:33

Date

Interpretation(s)
Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non
HDL-C as co-primary treatment target.
Risk Stratification for ASCVD (Atheroselerotic cardiovascular disease) by Lipid Association of India
Risk Category
Extreme risk group A.CAD with > 1feature of high risk group
B. CAD with > 1feature of Very high risk group or recurrent ACS (within I year) despite LDL-C <or =
S0 mg/dl or polyvascular disease
Very High Risk 1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3
Familial Homozygous Hypercholesterolemia
High Risk I. Three major ASCVID risk factors. 2. Diabetes with I major risk factor or no evidence of end organ
damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of asingle risk factor. 6. Coronary
Arery Calcium - CAC >300 AU. 7. Lipoprotein a>= S0mgldl 8. Non stenotic carotid plaque
Moderate Risk 2 major ASCVD risk factors
Low Risk 0- major ASCVD risk factors
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors
. Age > or 45 years in males and > or =55 years in females 3. Current Cigarette smoking or tobacco use
2. Family history of prematureASCVD 4. High blood pressure
5. Low HDL
Newer treatment goals and statin initiation thresholds basedon the risk eategories proposed by LAl in2020.
Risk Group Treatment Goals Consider Drug Therapy

Page 7 Of 8

Dr. Kauslk Das

Consultant - Pathologist cum
Laboratory Head

View Detalls ViewReport

PERFORMED AT :
Agilus Diagnostics Ltd.
Prabhat Sandhya Appt,Gr Floor,Mouza- Marigala, Ward No 13, District Hooghly Patient Ref. No, 2750000020778120
Dankuni, 712311
West Berngal, India
Tel : 9111591115, Fax: CIN - U74899PB1995PLCO45956
 DIAGNOSTICREPORT

agilus>» diagnostics
PATIENT NAME: HAFIZA BEGUM REF. D0CTOR:DR, RA THINDRA NATH BISWAS
CODE /NAME & ADDRESS : CO00111042 |ACCESSION NO :0269XD000334 | AGE/SEX 48 Years Fernale
SURE & CURE DIAGNOSTICS
PATTENT ID HAFIM2405750 DRAWN 04/04/2024 12:56:53
BEARING NO. 2440, PANDUA STATION BAZAR,
CUENT PATIENT ID: RECEIVED :04/04/2024 16:15:48
POST OFFICE LANE,P.S. PANDUA,
HOOGHLY 712149 ABHA NO REPORTED :04/04/2024 19: 48:18
9434562382

Test Report Status Final Results Biological Reference Interval Units

LDL-C (mg/dl) Non-HDL (mg/dl) LDL-C (mg/dl) Non-HDL (mg/dl)

Extreme Risk Group Category A <S0 (Optional goal 80 (Optional goal OR = 50 OR 80
OR = 30 ) <OR 60)
Extreme Risk Group Category B OR 30 <OR =60 > 30 60
Very High Risk 50 80 OR= 50 >OR= 80
High Risk <70 <|00 >OR= 70 >OR= |00
Moderate Risk <100 <I30 >OR= | 00 >OR= 130
Low Risk <100 <|30 >OR= |30* >OR= 160
"After an adequate non-pharmacological intervention for at least 3 months.
References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of
India Current Vascular Pharmacology, 2022, 20, 134-155.

**End Of Report**
Please vist www.agilusdiagnasttcs.com for related Test Information for this accession

cONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient 5. AGILUS Diagnostics confirms that all tests have been
named or identified in the test requisition form.
2. All tests are performed and reported as per the
turnaround time stated in the AGILUS Directory of Services.
3. Result delays could occur due to unforeseen
circumstances such as non-availability of kits / equipment
breakdown / natural calamities/technical downtime or any
other unforeseen event.
4. Arequested test might not be performed if:
i. Specimen received is insufficient or inappropriate
ii., Specimen quality is unsatisfactory
it. Incorrect specimen type
iv. Discrepancy between identification on specimen
container label and test requisition form
performed or assayed with highest quality standards, clinical
safety &. technical integrity.
6. Laboratory results should not be interpreted in isolation;
it must be correlated with clinical information and be
interpreted by registered medical practitioners only to
determine final diagnosis.
7. Test results may vary based on time of collection,
physiologlcal condition of the patient, current medication or
nutritional and dietary changes. Please consult your doctor
or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care
(91115 91115) within 48 hours of the report.
Agilus Dlagnostics Ltd
Fortis Hospital, Sector 62, Phase VII,
Mohall 160062

Page 8 Of 8

Dr. Kausik Das

Consuitant Pathologist cum
Laboratory Head

View Details View Report

PERFORMED AT:
Agilus Diagnostics Ltd.
Prabhat Sandhya Appt, Gr Foor,Mouza- Marlgalo, Ward No 13, Dlstrict HooghBy Patient Ref. No, }75000007078120
Dankuni, 712311
West Bengal, India
Tel : 9111591115, Fax : CIN - 074899PB1995PLC045956
 OIAGNOSTIC REPORT

MC5746
agilus>» dognostics

PATIENT NAME : MAFIZA BEGUM REF. DOCTOR:DR, RATHINDRA NATH BISWAS

oDE/NAME & ADDRESS :CO00111042 !AGE/SEX 48 Years Fernale
ACCESSION NO :0269XD000338
SURE & CURE DIAGNOSTcs iPATIENT ID HAFIM2405750 DRAWN 04/04/2024 12:59: 19
aFARING NO. 2440, PANDUA STATION RAZAR RECEIVED :04/04/2024 16:18:45
POST OFFICE LANE,P.S, PANDUA CLIENT PATIENT ID:
ABHA NO REPORTED :04/04/2024 19:37:06
HOOGHLY 712149
9434562382

Biological Reference Interval Units

Test Report Status Final Results

NEPHELOMETRY

C-REACTIVE PROIEIN, SERUM (QWANTITATIYE)

12,1 High < 5.0 rng/L
C-REACTIVE PROTEIN
METHOD: NEPHELOMETRY

Interpretstlon(s)
C-REACTIVE PROTEIN, SERUM (QUANTITATIVE)- TesttoDescription:
detet inflammation due to acute conditionsor to monitor the severity of disease in chronic conditions. CRP S one of
A CRP test measures the amount of CRP in the blood 4-6 hours of
Its rapld response to trauma or infection.Synthesis of CRP increases withir
the proteins commonty referred to as acute phase reactants. CRP is distinguished by
onset of inflammation, reaching peak values within 1-2 days. CRP levels also fall quickly afte resolution of inflammation since its half life is 6 hours. levels ir
different tests that measure CRP and each test measures a different range of CRP
This standard CRP test is not to be confused with a hs-CRP test. These are twoof protein observed In diseases that cause significant inflammation.
the blooc for different purposes. The standard CRP test measures hlgh levels
Test Interpretation: inflammation but will not identify its location or the cause.
Increased CRP level: In creasing amount of CRP in the blood suggests the presence of
SUspected bacteríal Infection: a high CRP level can confirm that you have a serlous bacterlal ínfection.,
have a chronic inflammatory disease or that treatment has not been effective.
Chronic inflammatory disease: high levels of CRP suggest a flare-up if you recovery from surgery, myocardial infarction, transplantation, infammatory bowel
disease,
Test1nc for dicated in the following clinical situations - monitoring
s indica
also prove useful In determinling disease progress or the effectveness of
infectious diseases. Measuring and charting C-reactive protein values can
rheumatic diseases and
treatments
of birth control pills or hormone replacement therapy (.e., estrogen). Higher leveis
of
CRP leves can be eievated in the later stages of pregnancy as well as with the use in people who have cancer.
CRP have elso bbeen observed in people who obese. CRP can also be increased individuals for
Recommendation: The hs-CRP test precisely detects lower levels of the protein than that measured by the standard CRP test and is also used to evakuate
disease, It measures CRP in the range from 0.15 to 20 ma/L.
risk of cardiovascular
Limltation: present, Levels may not increase in conditions like pregnancy, angina, seizures,
CRP leves n autotmune diseases may show ittie or no increase unless infection is Interpreted without a complete clinical history and evaluation.
asthma, common colc. The main limitation of CRP Is in its non-specific response and should not

**End of Report**
Please visit www.agilusdiagnostics.com for related Test Information for this accession

Page 1 Of 2

Dr. Chaitali Ray, PHD Dr.Anwesha

Chief Biochemist cum MRQA Chatterjee, MD,DipRCPath
(Histopathology)
Pathologlat
View Details View Report
PERFORMED AT:
Agilus Diagnostics Ltd.
PS Srijan Tech Park Building, Dn-52, Unit No. 2, Ground floor, Sector V, Salt Lake, Patient Ref, Na.Z75000002078126
Kolkata, 700091
West Bengal, India
Tel: 9111591115, Fax : 30203412
CIN - U74899PB1995PLCO45956
Emall : customercare.saltdake@agilus.in
 JAGNOSTICREPORT

MC-5746
agilus>»
PATIENTNAME : HAFIZA BEGUM REF, DOCTOR : DR. RATHINDPA NATH BISWAS
TODE /NAME & ADDRESS :CO00111042 IAGE/SEx 48 Years Female
ACCESSION NO :0269XD000338
sURE &CURE DIAGNOSTICS PATIENT ID DRAWN 04/04/2 024 12:59 19
HAFIM2405750
AFARING NO. 2440, PANDUA STATION BAZAR. 04/04/2024 16.1845
CUENT PATIENT 10: RECEIVED
POST OFFICE LANE,P.S. PANDUA,
ABHA NO
REPORTED :04/04/2 024 19:37:06
HOOGHLY 712149
9434562382

Test Report Status Biological Reference Interval Units

Final Results

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient
named or identified in the test requisition form.
2. All tests are performed and reported as per the
turnaround time stated in the AGILUS Directory of Services.
3. Result delays could occur due to unforeseen
circumstances SUch as non-availability of kits / equipment
|breakdown / natural calamities / technical downtime or any
other unforeseen event.
4. A requested test might not be performed if:
i. Specimen received is insufficient or inappropriate
il. Specimen quality is unsatisfactory
ii, Incorrect specimen type
iv. Discrepancy between identification on specimen
container label and test requisition form
5. AGILUS Diagnostics confirms that all tests have been
performed or assayed with highest quality standards, clinical
safety & technical integrity.
6. Laboratory results should not be interpreted in isolation;
it must be correlated with clinical information and be
interpreted by registered medical practitioners only to
determine final diagnosis.
7. Test results may vary based on time of collection,
physiological condition of the patient, current medication or
nutritional and dietary changes. Please consult your doctor
or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care
(91115 91115) within 48 hours of the report.

Agllus Diagnostlcs Ltd

Fortis Hospital, Sector 62, Phase VIII,
Mohall 160062

Page 2 of 2

Dr. Chaitall Ray, PHD Dr.Anwesha

Chiet Biochemist cum MRQA Chatterjee, MD, DipRCPath
(Histopathology)
Pathologlst
Vlew Detalls View Report
PERFORMED AT :
Agilus DIlagnostics Ltd.
PS Srijan Tech Park Building, Dn-52, Unit No. 2, Ground Floor, Sector V, Salt Lake,
Kolkata, 700091 Patient Ref No, Z7500000Z078176
West Bengal, India
Tel : 9111591 115, Fax : 30203412
CIN - U74899PB1995PLC045956
Email : CUstomercare.saltiake@agilus,in
 AGNOSTICRREPORT
agilus>»diagnostis

NAFIZA BEGUM REF. DOCTOR :DP, RATHINDRA NATH BISWAS

ATIENT NAME:
ADDRESS :C000111042 ACCESSION NO :0269XD000283 |AGE/SEX 48 Years Fernale
S0DE/NAME &DIAGNOSTICS DRAWN 04/04/2024 09: 38:45
PATIENT ID HAFIM2405750
SURE & CURE STATION BAZAR. RECEIVED 04/04/2024 13.09:28
2440, PANDUA
AFARING NO. LANE,P.S. PANDUA,
CIENT PATIENT ID:
POST OFMCE |ABHA NO REPORTED 04/04/2024 20:14:52
HOOGHLY 712149
9434562382

Results Biological Reference Interval Units

Test Report Status Final

MICROBIOLOGY

GRAN STAIN
SPUTUM
SPECIMEN SOURCE NUMBER OF
MODERATE PUS CELLS, FEW EPITHELIAL CELLS, MODERATE AND
AND CHAINS
GRAM STAIN GRAM POSITIVE COCCI SEEN IN PAIRS, TETRADS
FEW GRAM NEGATIVE BACILLI SEEN.

MICROSCOPIC EXAMINATON
METHOD: GRAMS STAIN +

Interpretation(s) in cinical
GRAM STAIN-GRAM STAIN the only method ermployed for the diagnostic iderntification of bacteria
Gram stain is the mostst important staining method in bacteriology. It is the first and usually stained smears from clinical specimens involves consideration of staining dark
of clinical specimens. Interpretatlon of gram which stain
specimens. It also serves to assess the quality two categories of genera: the Gram-positive,
of particular host cell types. It distinguishes two types of cells, Further details of the
bacteria
characteristic,morphology of the etiological agent and presence Gram-variable, and tend to show a mixture of the resuits s
light red. A few species are bserved. Comparing Gram stairn resuit to culture
purple. and the Gram-negative, which stain comma shaped Gram negative bacilli) are also
any other special features, including unusual shapes (such as
as monitoring quality assurance.
an exce llent internal method for
**End of Report**
for this accession
www.agilusdiagnostics.com for related Test Information
Please visit

Page 1 of 2

Dr.Himadri Mondal, MD
Consutant Microbiologist

View Detalls View Report

PERFORMED AT:
Agilus Diagnostics Ltd.
PS Srijan Tech Park Buildina, Dn-52. Unit No, 2. Ground Floor, Sector V, Salt Lake, Patient Rel.
Kolkata, 700091
West Bengal, India
Tel: 9111591115, Fax: 30203412
CIN -U74899PB1995PLC045956
Email : customercare.saltlake(0agilus,in
 MGNOSTIC REPORI

agilus>
BEGUM
PATIENT NAME : HAFIZA femole
ADDRESS :CO00111042
/NAME &
CODE DIAGNOSTICS AIEH
SURE & CURE PANDUA SIAION IAA
QEARING NO, 2440,
PANDUA.
P.S.
POST OFFICE LANE, ABIIA
HOOGHLY 712149
9434562382

Resulte Bigia Referene Interval Units

Test Report Status Final

REPORTING
cONDITIONS OF LABORATORY TESTING &
belongs to the patient 5. AGILUS Diagnostics confirrs that all tests have been
sample
1. It is presumed that the test requisition form. perforned or assayed with highest quality standards, clinical
named or identified in the test safety & technical integrity.
reported as per the
2. All tests are performed and AGILUS Directory of Services. 6. Laboratory resuts should not be interpreted in
isolation,
turnaround time stated in the be correlated with clinical inforrnation and be
unforeseen it rnust
3. Result delays could oCcur due to / equipmnent interpreted by registered rnedical practitioners only to
circumstances such as non-availability of kitsdowntime or any determine final diagnosIS.
breakdown / natural calamities / technical 7. Test results may vary based on tirne of
collection,
other unforeseen event.
physiological condition of the patient, current rmedication or
performed if:
4. Arequested test might not be nutritional and dietary changes. Plese consult your doctor
i. Specimen received is insufficient or inappropriate or call us for any clarification.
ii, Specimen quality is unsatisfactory Test results cannot be used for Medico legal purposes.
8
ii. Incorrect specimen type care
specimen 9. In case of queries please call cUstorner
iv. Discrepancy between identification on (91115 91115) within 48 hours of the report.
container label and test requisition form
Agllus Dlagnostics Ltd
Fortis Hospítal, Sector 62, Phase VIII,
Mohali 160062

Page 2 Of 2

Dr.Himadri Mondal, MD
Consultant Microbiologist

View Details View Report

PERFORMED AT:
Agilus Diagnostics Ltd.
PS Srijan Tech Park Building, Dn-52, Unit No. 2,
Kolkata, 700091 Ground Hoor, Sector V, Sat Lake, Patient Ref, Na, 775000007023{{4
West Bengal, India
Tel : 91115911 15, Fax :
30203412
CIN - U74899PB1995PLC045956
Email: cUstonercare.saltlakeagilus.in